Quick Answer
ENANTA PHARMACEUTICALS INC reported Total Assets of $280.73 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -25.5% in Total Assets from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $119.67 million | Q4 2013: $110.16 million | Q1 2014: $108.35 million | Q2 2014: $159.51 million | Q4 2014: $215.43 million | Q1 2015: $245.88 million | Q2 2015: $237.77 million | Q4 2015: $278.38 million | Q1 2016: $281.60 million | Q2 2016: $281.93 million | Q4 2016: $278.38 million | Q1 2017: $278.96 million | Q2 2017: $275.84 million | Q4 2017: $340.72 million | Q1 2018: $354.65 million | Q2 2018: $379.09 million | Q4 2018: $454.22 million | Q1 2019: $461.58 million | Q2 2019: $473.48 million | Q4 2019: $510.97 million | Q1 2020: $513.50 million | Q2 2020: $511.70 million | Q4 2020: $481.01 million | Q1 2021: $467.77 million | Q2 2021: $450.44 million | Q4 2021: $440.59 million | Q1 2022: $406.82 million | Q2 2022: $385.21 million | Q4 2022: $347.53 million | Q1 2023: $326.45 million | Q2 2023: $495.17 million | Q4 2023: $428.50 million | Q1 2024: $413.56 million | Q2 2024: $398.82 million | Q4 2024: $348.64 million | Q1 2025: $322.99 million | Q2 2025: $301.03 million | Q3 2025: $280.73 million | Q4 2025: $329.50 million.
- Over the full 14 years of available data (2012 to 2025), ENANTA PHARMACEUTICALS INC's Total Assets has grown by 438.2%.
- Historical annual values: Fiscal year 2025: $280.73 million | Fiscal year 2024: $376.65 million | Fiscal year 2023: $462.28 million | Fiscal year 2022: $375.41 million | Fiscal year 2021: $438.79 million | Fiscal year 2020: $486.13 million | Fiscal year 2019: $489.83 million | Fiscal year 2018: $414.23 million | Fiscal year 2017: $326.64 million | Fiscal year 2016: $281.28 million | Fiscal year 2015: $246.01 million | Fiscal year 2014: $155.42 million | Fiscal year 2013: $116.97 million | Fiscal year 2012: $52.16 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: